Abbott Launches Aveir Dual-Chamber Leadless Pacemaker in the UK

Abbott (NYSE: ABT) has reportedly begun rolling out its Aveir DR dual-chamber leadless pacemaker system in the United Kingdom. This launch follows the device’s CE mark approval for European commercialization in June 2024. The Aveir DR is the world’s first dual-chamber leadless pacemaker to treat patients with irregular or slow heart rhythms.

The system features Abbott’s i2i (implant-to-implant) technology, enabling synchronized wireless communication between the two leadless pacemakers. This advanced technology allows for efficient, beat-to-beat pacing based on the patient’s needs while reducing battery consumption. Unlike traditional pacemakers, the leadless system is implanted directly into the heart via a minimally invasive procedure, eliminating the need for leads and a pulse generator under the skin.

Abbott’s UK and Ireland General Manager Ross Campbell highlighted that the launch aims to improve the quality of life for people living with irregular heart rhythms across the UK. Abbott received FDA approval for the Aveir DR system in July 2023 and completed the first U.S. commercial cases later that year.